ESR1 and hepatocellular carcinoma: Antiproliferative effects of exogenous and extracellular IP6 were observed on human leukemia cells [31,32], human colon cancer cells [33] human breast cancer cell line, both estrogen receptor-positive and estrogen receptor-negative [34], cervical cancer [27], prostate cancer [35,36], and hepatoma cell lines [37].